Projects

Zoetis’ Animal Vaccine Research and Manufacturing Complex, Suzhou

In April 2018, global animal health company Zoetis began constructing a new animal vaccine manufacturing and research facility in Suzhou, China.

Project Type
Animal vaccine manufacturing complex
Location
Suzhou, China
Construction Started
April 2018
Expected Completion
2021
Owner
Zoetis

In April 2018, global animal health company Zoetis began constructing a new animal vaccine manufacturing and research facility in Suzhou, China.

The new facility will house a global manufacturing and supply facility, as well as a research and development (R&D) centre.

The project is expected to be completed and awarded a certificate of good manufacturing practices (GMP) from the Chinese Ministry of Agriculture by 2021. Once in operation, it is also expected to generate more than 100 new jobs in R&D and manufacturing.

Purpose of Zoetis Suzhou vaccine manufacturing complex

The animal vaccine manufacturing facility will be used for the development and production of high-quality vaccines for livestock, fish and companion animals. The products will be sold primarily in the Chinese animal health market.

The plant will allow Zoetis to help livestock farmers in China meet the increasing domestic demand for safe supply of pork, milk, beef and fish in large quantities. It will become the company’s second manufacturing complex in the country, joining an existing site in Jilin.

The vaccines manufactured at the new facility will help safeguard animals from the strains of infectious diseases.

Zoetis Suzhou vaccine research and manufacturing facility details

The state-of-the-art Suzhou vaccine research and manufacturing complex will be developed in multiple phases. With a total of 43,000m², the first phase will accommodate six main buildings for vaccine manufacturing and an R&D laboratory.

“China is one of the world’s largest animal health markets, with reported $4.3bn of sales in 2017.”

The campus will also include a production facility, a warehouse and a central utility building.

In addition, the campus will be equipped with advanced technologies for the production of viral and bacterial medicines and include a pilot-scale manufacturing facility for the development of new vaccines.

Contractors involved

Zoetis appointed engineering design, architecture, project and construction management services provider PM Group for the conceptual design and master planning of the new complex, while Australian building construction services contractor Cockram will assist in overall construction management.

Animal health market in China

China is one of the world’s largest animal health markets, with reported $4.3bn of sales in 2017 and witnessing a compound annual growth rate between 7% and 10%. The growth was primarily due to vaccines sales.

China also has one of the world’s largest pig market and raises approximately 700 million hogs a year.

In addition, spending on pet medications and vaccines in 2017 exceeded $300m, and the pet healthcare market and ownership in the country continues to grow.

Marketing commentary on Zoetis

Founded in 2013, Zoetis is engaged in producing medicine and vaccinations for livestock farmers and veterinarians. The company develops and manufactures a wide range of animal health medicines and vaccines, diagnostic products, genetic tests and biodevices.

Headquartered in Parsippany, New Jersey, Zoetis operates in more than 45 countries. Its products are sold in more than 100 countries worldwide.

Zoetis operates a network of 25 manufacturing sites across 12 countries, with a workforce of roughly 9,000. The company reported revenue of approximately $5.3bn in 2017.

Zoetis opened a medicated feed additive products manufacturing facility in 2015 for the production of water-soluble and pre-mix products, including Linco-Spectin®, Lincomix®, Tilmicosin® and COT (Check-O-Tox®).

Related Projects